Anti-Mda5 Antibody as a Potential Diagnostic and Prognostic Biomarker in Patients With Dermatomyositis

Oncotarget - United States
doi 10.18632/oncotarget.15716
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Anti‐transcriptional Intermediary Factor 1‐γ Antibody as a Biomarker in Patients With Dermatomyositis

Journal of Dermatology
DermatologyMedicine
2019English

Serum KL‐6 Level Is a Prognostic Marker in Patients With Anti‐MDA5 Antibody‐positive Dermatomyositis Associated With Interstitial Lung Disease

Journal of Clinical Laboratory Analysis
AllergyImmunologyBiochemistryPublic HealthMedical Laboratory TechnologyClinical BiochemistryHematologyMicrobiologyEnvironmentalOccupational Health
2019English

G448 Juvenile Dermatomyositis Associated With Interstitial Lung Disease: Would Anti-Mda5 Antibody Detection Improve Early Diagnosis and Management?

2018English

Evaluation of Plasma Albumin as a Potential Prognostic Biomarker in Patients With Traumatic SIRS

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2017English

Serum miR-26a as a Diagnostic and Prognostic Biomarker in Cholangiocarcinoma

Oncotarget
Oncology
2015English

Anti‐TIF‐1β Antibody in Dermatomyositis

British Journal of Dermatology
DermatologyMedicine
2019English

Hypomyopathic Dermatomyositis Presenting With Idiopathic CD4 T-Lymphocytopenia and Delayed Anti-Mda5 Positivity

Cureus
2019English

Intravenous Immunoglobulin Contributes to Control Anti-Melanoma Differentiation-Associated Protein 5 (MDA5) Antibody-Associated Dermatomyositis With Palmar Violaceous Macules/Papules

British Journal of Dermatology
DermatologyMedicine
2017English

Circular RNA Hsa_circ_0078602 May Have Potential as a Prognostic Biomarker for Patients With Hepatocellular Carcinoma

Oncology Letters
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy